Form D · Biotechnology
SUTOL BIO, Inc.
Cambridge, MA · CIK 0002164602
Offering snapshot reported Nov 10, 2026 · SEC filing
- Reported sold
- $474K Offering amount: $474K
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $14K Reported outside-investor minimum
- First sale
- Nov 20, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 10, 2026 | Initial | $474,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-604258
Simple Agreement for Future Equity (SAFE)
Source: Form D, filed Nov 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert S Langer | Director |
| Seungho Lee | Director, Executive |
| Matt J Murphy | Director, Executive |
| Carlo Giovanni Traverso | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
750 Main St
Cambridge, MA, 02139
Cambridge, MA, 02139